Michael Fluck

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network

Caroline Voskens, Simone M. Goldinger, Carmen Loquai et al. · PLoS ONE · 2013 · 470 citations · Full text

Medicine, Oncology, Pharmacology +16

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma

Lisa Zimmer, Julia Vaübel, Peter Mohr et al. · PLoS ONE · 2015 · 291 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

Grant A. McArthur, Michele Maio, Ana Arance et al. · Annals of Oncology · 2016 · 246 citations · Full text

Medicine, Oncology, Pharmacology +12

Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Lisa Zimmer, Elisabeth Livingstone, Jessica C. Hassel et al. · The Lancet · 2020 · 242 citations

Medicine, Immunology, Oncology +14

Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Elisabeth Livingstone, Lisa Zimmer, Jessica C. Hassel et al. · The Lancet · 2022 · 108 citations

Medicine, Immunology, Oncology +16